- Home/
- Industry Perspectives

| 6 min read
As soaring costs and logistical complexity strain traditional cell therapy models, in vivo CAR T is prompting a fundamental rethink of how advanced therapies are manufactured and scaled.
| 1 min read
The expanded partnership reflects strong demand for Lonza’s global biologics outsourcing platform, spanning diversified clinical and commercial manufacturing programs.


















